Are knee injections the right next step

Pain that keeps returning despite “doing the right things” is usually the moment people start weighing up injections. A common UK scenario is an adult with knee osteoarthritis who has kept up with strengthening work for 8–12 weeks, adjusted activity, tried simple pain relief, and perhaps lost a few kilograms — yet the knee still swells after a normal day’s walking, wakes them at 2am, or makes stairs feel like a negotiation rather than a movement.

Even at that stage, injections tend to sit on top of the foundations rather than replace them. In usual UK care pathways, exercise and strength work, weight optimisation where relevant, footwear choices, pacing and simple analgesia/physiotherapy are commonly treated as the core of osteoarthritis care, with injections considered when pain and swelling remain troublesome despite these measures or during more severe flares that limit day‑to‑day function. (That balance matters because the best evidence for long‑term knee function still comes from ongoing strength and activity management, not from any single injection.)

From a practical standpoint, the main injection categories discussed in UK clinics fall into a few buckets:

• Corticosteroid (“cortisone”): aims to calm an inflammatory flare, particularly when there is obvious swelling.
• Hyaluronic acid (“gel” / viscosupplement): a joint‑fluid supplement that may help lubrication and symptoms for several months in some people.
• PRP (platelet‑rich plasma): made from a sample of the person’s own blood, aiming to influence the joint environment rather than “cushion” it.
• Arthrosamid (polyacrylamide hydrogel): a long‑acting, non‑biodegradable hydrogel designed to remain in the joint and provide mechanical cushioning; it is a symptom‑modifying option rather than cartilage regrowth.
• mFAT / BMAC orthobiologics: injections based on fat‑derived tissue or bone marrow, usually involving a harvest step before the joint injection; these are often described as promising but still investigational for knee osteoarthritis.

These treatments are generally delivered as outpatient, image‑guided intra‑articular injections, rather than an operation, and many people walk in and out on the same day; the main exception is that mFAT or BMAC typically add a same‑day collection procedure before the injection. Because sudden, severe deterioration can need urgent assessment, this section stays focused on “is an injection the next step?”, and the specific urgent warning signs are dealt with separately.

In real terms, injections aim to shift the day‑to‑day baseline — less pain, easier walking, better sleep, and a more reliable knee for a period of time — but they do not “cure” osteoarthritis, and response varies between individuals and between products. The decision usually comes down to questions such as: is the problem mainly a swollen flare or persistent mechanical pain; how long a benefit is realistic; and whether the priority is a short‑term reset (often steroid) or a longer‑lasting option (where a hydrogel such as Arthrosamid may be considered in the right clinical context).

What to do with a swollen arthritic knee

Swelling in knee osteoarthritis often comes and goes: a knee that was tolerable on Monday can feel tight, stiff and “puffy” by Wednesday, sometimes after extra stairs or a longer walk, and sometimes with no obvious trigger. In many cases it settles again over days, but the first priority is to separate a familiar osteoarthritis flare from a problem that needs urgent NHS assessment. (This logic applies whether the knee is arthritic or not: sudden or severe change needs checking before anyone thinks about an elective injection.)

Red flags that need urgent assessment (not an injection booking)

A knee that becomes very painful, badly swollen, hot, deformed, or where the person cannot bear weight should be treated as urgent; fever or feeling unwell alongside a hot knee is particularly concerning. These features can point to problems such as infection, a significant injury, or an inflammatory arthritis flare, where delaying assessment to “try an injection” is the wrong direction of travel. (A swollen knee that appears rapidly over hours, rather than building over days, is another practical warning sign in real-world triage.)

A simple flare plan when it’s not urgent

For a non-urgent flare (for example, swelling that builds after activity and there are no red flags), self-care advice commonly centres on short-term load reduction and symptom control while the joint calms down. Common elements include relative rest for a short period, ice/heat depending on what helps, and simple pain relief/topical anti-inflammatories where appropriate, alongside pacing rather than pushing through sharp pain. If pain and swelling are not improving over a few weeks, arranging a GP review is sensible, as persistent swelling may need a reassessment of diagnosis and a more structured plan.

Steroid (cortisone) injections: when swelling dominates

Steroid joint injections are often framed as an option when pain remains troublesome despite other measures, or during a significant flare that is limiting function. In an osteoarthritic knee, the steroid is used to calm inflammation in the joint lining, which can reduce pain and swelling for the short term. Evidence summaries also emphasise what steroids do not do: they do not repair cartilage and are not considered disease-modifying in osteoarthritis.

Steroid injections are also usually limited in frequency. Evidence discussed in injection overviews includes trials where repeated, regular steroid injections over long follow-up were linked with cartilage volume loss compared with placebo, even when pain relief was similar—one reason many clinicians reserve steroids for specific flares or situations rather than repeating them routinely. Potential systemic side-effects (for example, temporary effects on blood sugar) are another reason dosing is typically cautious.

Where other injections fit if swelling keeps returning

If the pattern is “swelling settles, then returns every few weeks”, clinicians often consider whether an initial steroid is needed to settle an inflamed knee before moving to an option aimed more at ongoing symptoms. Hyaluronic acid and PRP are commonly positioned as treatments that may help background pain and function over months in some people, rather than as a first response to a very hot, acutely swollen knee; longer-acting options such as polyacrylamide hydrogel are usually considered once a flare is under control and suitability has been assessed. In UK practice this sequencing is often discussed in a single consultation that reviews recent swelling episodes, current function (for example, walking tolerance in minutes), and whether red flags have been excluded.

Once urgent causes have been ruled out, an AMSK suitability assessment is one route some people use to explore whether an image-guided injection is appropriate for their current stage and symptom pattern.

How steroid, gel, PRP and Arthrosamid injections differ

Choosing between the common knee injections is usually less about which one is “strongest” and more about what problem is being targeted (an inflammatory flare, reduced joint lubrication, or longer‑term symptom control) and what kind of time‑horizon is realistic (weeks, months, or years). Published evidence and clinical summaries also differ in strength between options, which matters when weighing repeat treatment, side‑effects and cost.

• Steroid (corticosteroid): anti‑inflammatory “reset” for a painful, swollen knee; fastest onset; benefit is typically short‑term; repeat injections are commonly limited.
• Hyaluronic acid (HA) gel / viscosupplement: aims to improve lubrication and reduce friction; onset tends to be slower than steroid; in responders, relief is often for months and may require repeat courses.
• PRP (platelet‑rich plasma): prepared from the person’s own blood; aims to influence inflammatory signalling and joint “homeostasis” rather than mechanically cushion the joint; evidence is mixed and benefits commonly sit in the months range.
• Arthrosamid (polyacrylamide hydrogel): a non‑biodegradable hydrogel intended to remain in the joint and integrate with the synovial lining; designed for longer‑acting symptom relief, though comparative long‑term data are still developing.

Steroid injections (corticosteroid)

A corticosteroid injection is primarily an anti‑inflammatory treatment aimed at calming synovitis (irritation of the joint lining) when the knee is hot, swollen or sharply flared. Injection overviews commonly characterise the payoff as quick symptom reduction—often noticeable within days—rather than a durable change to the course of osteoarthritis.

The main practical limitation is frequency. Evidence summaries emphasise that repeated steroid dosing is usually constrained because of concerns about potential cartilage effects and systemic side‑effects (for example, short‑term effects on blood glucose in people with diabetes), so it is rarely treated as a “maintenance” injection in knee OA.

Bottom line: steroid suits a swelling‑dominant pattern and a short time‑horizon, especially when the priority is getting out of a flare. It is not considered disease‑modifying in osteoarthritis.

Hyaluronic acid (HA) gel / viscosupplementation

HA injections are usually framed as a viscosupplement: an attempt to supplement joint fluid and improve lubrication and shock‑absorption, which may reduce friction‑related pain in some people with mild to moderate knee OA. Reviews typically report a slower onset than steroid, but symptom improvement can last for months in responders.

It is also important to separate symptom relief from tissue restoration. HA is generally positioned as a non‑surgical outpatient injection that can improve pain and function in some cases, but does not regrow cartilage, and repeat treatment is common when the benefit wears off.

Bottom line: HA tends to be chosen for a steady ache / stiffness pattern when a “months‑level” improvement is a reasonable bet, with the understanding that response varies and repeat courses are common.

PRP (platelet‑rich plasma)

PRP is made by taking a blood sample and concentrating the platelet‑rich portion before injecting it into the knee. The rationale is biologic signalling—platelet‑derived factors that may modulate inflammation and support the joint environment—rather than acting as a lubricant or physical cushion.

Across trials and clinical series, results are mixed: some studies report better pain and function than placebo or HA for certain groups, while others show smaller differences, and outcomes can be influenced by how PRP is prepared (methods are not standardised across clinics). Where benefit occurs, it is commonly reported over months rather than years.

Bottom line: PRP is often considered when the goal is a biologic “nudge” towards symptom improvement over months, accepting that the evidence base is variable and the treatment pathway is not standardised.

Arthrosamid (polyacrylamide hydrogel)

Arthrosamid is a non‑biodegradable polyacrylamide hydrogel injected into the knee (typically under ultrasound guidance). Unlike HA (which behaves more like a temporary viscosupplement) or PRP (a biologic signal), this hydrogel is designed to remain long‑term and integrate with the synovial lining, providing a more sustained mechanical cushioning effect and potentially modifying the joint environment in that way.

Available clinical data and specialist summaries commonly report longer-lasting symptom relief after a single injection in selected patients, but much of the current evidence is based on cohorts and open‑label follow‑up rather than large head‑to‑head trials against every other injection type. It is also not a regenerative treatment and is not intended to restore lost cartilage.

Bottom line: Arthrosamid is generally considered when a single‑injection, longer‑lasting symptom‑modifying option is the priority, while accepting that suitability depends on the individual knee and that long‑term comparative evidence is still evolving.

Some clinics use a structured suitability process (often incorporating imaging review and symptom profiling) to match the mechanism—anti‑inflammatory, viscosupplement, biologic signalling, or long‑acting hydrogel—to the person’s pattern of pain and swelling.

What knee injections usually cost in the UK

Private prices for knee injections in the UK can look confusing because two quotes that are both “one injection” may include very different things (for example, ultrasound guidance, follow‑up, or a package of multiple injections). A useful way to make sense of it is to separate the type of injectate (steroid vs gel vs PRP vs hydrogel) from the service around it (consultation, imaging, and aftercare), because it is often the second part that explains why figures differ widely between providers.

Typical private self‑pay ranges (illustrative, not a national tariff)

Across published UK clinic fee schedules, steroid (cortisone) injections tend to sit at the lowest end of the market, while hyaluronic acid (“gel”), PRP, and longer‑acting hydrogel options are typically priced higher. PRP is commonly sold either per injection or as a multi‑injection course, which can make headline prices hard to compare.

Arthrosamid (polyacrylamide hydrogel) is usually priced in a different bracket again, commonly quoted as a single‑injection treatment with a higher upfront cost, and sometimes offered as a package that bundles imaging and follow‑up.

What usually drives the price difference

In UK self‑pay practice, three “line items” often explain most variation between quotes on the same injection type:

• Consultation and assessment: whether the price includes a first specialist appointment and whether there is a formal review point.
• Imaging and guidance: whether ultrasound guidance is included in the injection fee, and whether new imaging is bundled.
• Number of injections and follow‑up window: whether the plan is priced as a single appointment or a course (for example, a multi‑injection PRP package), and whether follow‑up support extends over time.

A practical example shows why this matters: one quote might advertise a low per‑injection PRP figure but charge separate consultation and plan additional injections later; another might look higher because it already includes multiple injections and review.

NHS vs self‑pay vs private medical insurance (PMI)

On the NHS, intra‑articular injections (most often corticosteroid when clinically indicated) may be offered via hospital, interface, or community MSK services—but availability and waiting time can vary between areas of England, Scotland, Wales and Northern Ireland. Many newer or elective injection options may not be routinely available via NHS commissioning, and private medical insurance policies vary in what they will cover.

Mixing NHS and private care: a funding rule issue

Some commissioning policies discourage patients from having a mixture of privately funded and NHS‑funded care for the same episode of treatment. This is primarily a governance issue rather than a clinical safety point, but it can affect planning.

Questions that clarify value before booking

To compare offers without getting lost in headline figures, it usually helps to get a written breakdown that answers three concrete points:

• “Is the price per knee, per injection, or for a course (e.g., 3 injections)?”
• “Does it include ultrasound guidance and follow‑up?”
• “What happens if the response is partial at 6–12 weeks—repeat injection, different injectate, or a new plan?”

Where a tailored, written quote is needed (including whether one knee or both knees are being considered), an enquiry can set out what is included in the proposed pathway—consultation, ultrasound‑guided injection, and follow‑up—before any appointment is booked.

Where fat and bone marrow injections fit in

Orthobiologic injections such as microfragmented adipose tissue (mFAT) and bone marrow aspirate concentrate (BMAC) tend to enter the conversation after simpler injectables have been considered, because they are trying to do something different: deliver a concentrated mix of the body’s own cells and signalling molecules into an osteoarthritic joint environment, rather than mainly “switching off” inflammation (steroid) or changing joint mechanics with a gel or hydrogel. That biologic rationale—particularly for early to moderate knee osteoarthritis—is the main reason these options remain “on the menu”, even though they often sit outside routine NHS pathways and the evidence base is still developing.

mFAT (microfragmented adipose tissue): what happens on the day

mFAT uses a small volume of a person’s own fat—commonly taken from the abdomen or upper thigh—as the starting material. In a single outpatient visit, the fat is collected under local anaesthetic, minimally processed (to “microfragment” and concentrate tissue components), and then injected into the knee joint, usually with imaging guidance. The key practical point is that it is still an injection-based pathway, but it has a brief harvest step before the knee injection, so it feels more involved than a standard in-clinic steroid or HA appointment.

In regenerative-medicine overviews, the proposed aim is typically framed as supporting the joint environment (for example by influencing inflammatory signalling and pain pathways), so outcomes are usually framed as symptom and function changes rather than structural reversal of osteoarthritis.

BMAC (bone marrow aspirate concentrate): a similar idea, a different harvest site

BMAC follows a similar two-step logic, but uses bone marrow instead of fat. Marrow is typically drawn from the pelvic bone under local anaesthetic, processed to concentrate the aspirate, and injected into the knee in the same session. Because the harvest is from bone rather than soft tissue, BMAC is often perceived as a bigger undertaking than PRP (which starts with a simple blood draw), even though it is usually delivered as an outpatient procedure.

Evidence and expectations: why interest persists, and what remains uncertain

Across orthobiologics reviews, the clinical signal for both mFAT and BMAC is broadly similar: small randomised trials and observational cohorts suggest some patients—particularly those with less advanced OA—may experience improvements in pain and function, but there is a shortage of large, long-term, standardised studies that clearly define best candidates, dosing, preparation methods and durability. For that reason, specialist texts continue to describe these treatments as promising but investigational, with open questions about standardisation and cost-effectiveness.

A practical way of stating the “best-case vs typical-case” expectation is this: the best-case hope is meaningful symptom improvement that supports walking tolerance and day-to-day function for a period of time; the typical case, based on current summaries, is more variable—ranging from noticeable benefit to minimal change—and these treatments are not presented as a reliable way to regenerate cartilage in established osteoarthritis.

How mFAT/BMAC differ from PRP and Arthrosamid in practice

Compared with PRP, mFAT and BMAC usually involve a harvest + processing step rather than a blood draw, which is one reason they are commonly positioned as more complex private treatments. Compared with Arthrosamid (polyacrylamide hydrogel), the underlying mechanism is different: mFAT/BMAC aim for biologic support using autologous material, whereas the hydrogel approach is designed to provide longer-lasting mechanical cushioning by a material that remains in the joint.

In UK practice, the combination of limited guideline adoption, variable study results, and the added procedural steps means access is generally through self-funded pathways, and the cost is often higher than simpler injection options because of the harvesting and processing involved.

Do ultrasound guided injections work better

Paying extra for ultrasound guidance is usually about reducing the chances that an injection ends up outside the joint. In practical terms, an ultrasound‑guided injection means the clinician uses a live ultrasound image to identify the joint space and watch the needle tip enter it, rather than relying only on surface landmarks. This is typically done in an outpatient clinic setting, without a general anaesthetic.

For the knee, the evidence on accuracy is strong and consistent. A 2025 systematic review pooling comparative studies reported technical accuracy in the mid‑90% range for ultrasound guidance versus the low‑80% range for landmark guidance (reported as 95.4% vs 82.0%).

Accuracy matters because a “missed” injection can mean less symptom relief and, sometimes, a more painful experience. In the same 2025 review, nearly all studies that measured symptom response reported better pain and function outcomes in the ultrasound‑guided groups, although the size of the difference varied between trials and follow‑up was often short.

For the hip, the best available data are less often randomised, but observational series are generally supportive on technical success and safety. In one cohort of 78 patients, response to an ultrasound‑guided intra‑articular anaesthetic injection had 91.7% diagnostic accuracy for intra‑articular pathology, and the authors reported no injection‑related complications. Separately, a series of 276 ultrasound‑guided hip injections performed for MR arthrograms achieved 99.3% adequate intra‑articular fill, again with no vascular complications reported.

Where this translates into a practical choice is that ultrasound guidance is often most worth prioritising when the injection is high‑value or technically demanding—for example, when treating a deeper joint (such as the hip), when previous landmark injections have not helped (raising the possibility of incomplete intra‑articular delivery), or when a joint is difficult to assess by feel (for instance, marked swelling or body‑shape factors). The trade‑off is that ultrasound requires equipment and expertise, and researchers are still clarifying how cost‑effective routine ultrasound guidance is across different clinics and real‑world settings—even though the accuracy advantage itself is clear.

When comparing providers, practical checks often include:

• whether the injection is ultrasound‑guided as standard (and who performs the scan)
• what counts as intra‑articular placement for that specific joint (knee vs hip)
• what follow‑up is offered if pain relief is partial at 6–12 weeks

Beyond the technical checklist, the key takeaway is that the decision tends to run in a simple sequence: persistent osteoarthritis symptoms lead to choosing an injection type with a realistic time‑horizon, funding constraints narrow what is feasible in the UK, and then image‑guided delivery becomes a quality lever—particularly for the hip and for higher‑cost knee injections—because it reduces the likelihood that an otherwise appropriate treatment is undermined by inaccurate placement.

1. [1] Accuracy and efficacy of intra-articular knee injections/aspirations under ultrasound versus landmark guidance: A systematic review. (2025). https://doi.org/10.1097/PHM.0000000000002803 https://doi.org/10.1097/PHM.0000000000002803